Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure:A Phase II Danish Multicentre Study by Kastrup, Jens et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with
Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic
Heart Failure
Kastrup, Jens; Schou, Morten; Gustafsson, Ida; Nielsen, Olav W; Møgelvang, Rasmus;
Kofoed, Klaus F; Kragelund, Charlotte; Hove, Jens Dahlgaard; Fabricius-Bjerre, Andreas;
Heitman, Merete; Haack-Sørensen, Mandana; Lund, Lisbeth Drozd; Johansen, Ellen
Mønsted; Qayyum, Abbas Ali; Mathiasen, Anders Bruun; Ekblond, Annette
Published in:
Stem Cells International
DOI:
10.1155/2017/8506370
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Kastrup, J., Schou, M., Gustafsson, I., Nielsen, O. W., Møgelvang, R., Kofoed, K. F., ... Ekblond, A. (2017).
Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived
Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study. Stem Cells
International, 2017, [8506370]. https://doi.org/10.1155/2017/8506370
Download date: 03. Feb. 2020
Clinical Study
Rationale and Design of the First Double-Blind, Placebo-
Controlled Trial with Allogeneic Adipose Tissue-Derived
Stromal Cell Therapy in Patients with Ischemic Heart
Failure: A Phase II Danish Multicentre Study
Jens Kastrup,1,2 Morten Schou,3,4 Ida Gustafsson,5 Olav W. Nielsen,6 Rasmus Møgelvang,1
Klaus F. Kofoed,1,7 Charlotte Kragelund,3 Jens Dahlgaard Hove,5,8
Andreas Fabricius-Bjerre,6,9 Merete Heitman,6,9 Mandana Haack-Sørensen,2
Lisbeth Drozd Lund,2 Ellen Mønsted Johansen,2 Abbas Ali Qayyum,1
Anders Bruun Mathiasen,1 and Annette Ekblond2
1Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
3Department of Cardiology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
4Department of Radiology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
5Department of Cardiology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
6Department of Cardiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
7Department of Radiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
8Department of Radiology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
9Department of Radiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
Correspondence should be addressed to Jens Kastrup; jens.kastrup@regionh.dk
Received 31 May 2017; Accepted 24 August 2017; Published 19 September 2017
Academic Editor: Bojan Vrtovec
Copyright © 2017 Jens Kastrup et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Ischemic heart failure (IHF) has a poor prognosis in spite of optimal therapy. We have established a new
allogeneic Cardiology Stem Cell Centre adipose-derived stromal cell (CSCC_ASC) product from healthy donors. It is
produced without animal products, in closed bioreactor systems and cryopreserved as an oﬀ-the-shelf product ready to use.
Study Design. A multicentre, double-blind, placebo-controlled phase II study with direct intramyocardial injections of
allogeneic CSCC_ASC in patients with chronic IHF. A total of 81 patients will be randomised at 2 : 1 to CSCC_ASC or
placebo. There is no HLA tissue type matching needed between the patients and the donors. Methods. The treatment will
be delivered by direct injections into the myocardium. The primary endpoint is change in the left ventricle endsystolic
volume at 6-month follow-up. Secondary endpoints are safety and changes in left ventricle ejection fraction, myocardial
mass, stroke volume, and cardiac output. Other secondary endpoints are change in clinical symptoms, 6-minute walking
test, and the quality of life after 6 and 12 months. Conclusion. The aim of the present study is to demonstrate safety and
the regenerative eﬃcacy of the allogeneic CSCC_ASC product from healthy donors in a double-blind, placebo-controlled,
multicentre study in patients with IHF.
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1. Background
Ischemic heart disease (IHD) caused by coronary artery
disease is the most common cause of death with more than
17 million deaths worldwide each year and the major cause
of hospital admissions [1]. It is an increasing economic
health problem due to increasing morbidity in an ageing
population. Conventional therapies have reduced the mortal-
ity of IHD signiﬁcantly, but left an increasing number of
patients with chronic IHD and/or ischemic heart failure
(IHF) without further treatment options.
When looking for new treatment options, regenerative
therapy with stem cells has been investigated intensively in
several clinical studies in patients with acute or chronic
IHD [2–4]. Several diﬀerent cell populations have been inves-
tigated. Initially, it was mainly bone marrow-derived mono-
nuclear cells (MNCs), mesenchymal stromal cells (MSCs),
CD34+, CD133+, and endothelial progenitor cells. Later, cell
populations have been isolated from the adipose tissue (adi-
pose-derived mesenchymal stromal cells (ASCs)), placenta,
umbilical cord, the heart, and several other tissues [2]. Pres-
ently, no consensus exists about the best cell type for clinical
regenerative therapy.
The presence of MSC-like cells in all tissues of the body
indicates their importance, and preclinical studies indicate
that these cells have regenerative capacity regardless of tissue
origin [4]. Most clinical studies have used BM-MSCs. How-
ever, from a feasibility point of view, ASCs are superior to
BM-MSCs as a higher yield of ASCs can be isolated from
abdominal adipose tissue compared to MSCs from the bone
marrow. [5] Furthermore, ASCs grow faster than BM-
MSCs during culture expansion [6].
We have conducted three clinical studies with autologous
culture-expanded BM-MSCs and ASCs in patients with IHD
with or without heart failure [7–11]. The treatments have
been safe and the regenerative eﬃcacy promising. The studies
demonstrated improvements in left ventricular ejection
fraction, heart tissue remodeling, exercise capacity, and relief
of symptoms.
To implement and disseminate a new clinical therapy
with stem cells to all potential candidates, safety and eﬃcacy
have to go hand in hand with feasibility; it has to be logisti-
cally easy to request and perform the treatment. However,
there are many logistical obstacles in the presently used
clinical models for autologous MSC therapies within cardiol-
ogy: Invasive harvesting of bone marrow or aspiration of
abdominal adipose tissue in all patients was followed by
several weeks of culture expansion with a huge variation in
proliferation rate and cell yield from patient to patient. This
makes it diﬃcult to treat patients with a standardised number
of cells in clinical studies. Moreover, it is logistically diﬃcult
to schedule the treatment procedure due to large variations in
cell production time.
Additionally, the number of cells delivered to the patient
may be of importance for the treatment eﬃcacy and the
patients may need more than one treatment session to get
relief from cardiac symptoms.
We have tackled these serious hurdles by establishing
new ASC cultivation protocols with human platelet lysate
in closed bioreactor systems and by establishing a centralised
production of an allogeneic Cardiology Stem Cell Centre
adipose-derived stromal cell (CSCC_ASC) product from
healthy donors, which can be stored in nitrogen vapour con-
tainers as an oﬀ-the-shelf product in the hospital ready to be
used without any delay.
Thisnewlydevelopedcryopreservedproduct,CSCC_ASC,
from healthy donors was safe and feasible in a phase I
study in patients with IHF [12]. In addition, we observed
a tendency towards eﬃcacy in patients although the study
was not powered for that.
This study was established to investigate both the safety
and the eﬃcacy with regard to the regenerative potential of
this newly developed CSCC_ASC product. The present
report will outline the rationale and design of this multicen-
tre, double-blinded, placebo-controlled phase II study using
intramyocardial delivered allogeneic CSCC_ASC in patients
with IHF.
2. Methods
2.1. Study Design and Population. The study protocol
complies with the Declaration of Helsinki and was approved
by the Danish National Committee on Health Research
Ethics (number 1717872) and Danish Medicines Agency
(EudratCT number 2015-001560-19). The study is registered
with clinicalTrials.gov (NCT02387723). The local Good
Clinical Practice Unit from the capital region of Denmark
will monitor the study.
The study will include 81 patients with IHF between
30 and 85 years of age with reduced left ventricular ejec-
tion fraction (LVEF) (≤45%) evaluated by echocardiogra-
phy, New York Heart Association (NYHA) classes II-III,
no further revascularization options and on maximal toler-
able heart failure medication. Inclusion and exclusion
criteria are described more in detail in Table 1.
The patients will be screened and followed locally in the
four participating clinical cardiology sites. All patients will
be treated centrally at the Department of Cardiology, Rig-
shospitalet University Hospital Copenhagen in a 2 : 1 rando-
misation with either CSCC_ASC or placebo (isotonic saline).
Patients will have follow-up visits 1, 3, 6, and 12
months after treatment for safety and eﬃcacy evaluation
(Figure 1 and Table 2).
2.2. Cell Production. The investigational cell product,
CSCC_ASC, will be produced in the Cardiology Stem Cell
Centre, Rigshospitalet University Hospital Copenhagen in
an approved good manufacturing practice (GMP) facility fol-
lowing the description in an approved Investigational Medic-
inal Product Dossier.
The cell product will derive from 5 to 7 healthy donors.
The donor eligibility will be determined by a donor interview,
a questionnaire, and testing for infectious disease markers
including human immunodeﬁciency virus (HIV) and human
T-cell lymphotropic virus (HTLV) types I/II by serum
analyses within 30 days prior to liposuction. In addition, a
blood sample will be drawn on the day of donation for
repeated serology and nucleic acid testing of HIV and
hepatitis B and C.
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The donors will have an abdominal liposuction
(100–150mL of lipoaspirate). The preparation of lipoaspi-
rates, isolation of stromal vascular fractions, and expansion
of adipose-derived stromal cells in Quantum Cell Expansion
Systems (Terumo, US) will be performed as previously
described [12–14]. Each CSCC_ASC treatment vial will
consist of ASCs from one donor only.
The production unit will produce and deliver both the
CSCC_ASC and the placebo (isotonic saline) batches based
on the randomisation code. It will label the Investigational
Medicinal Product (IMP) and placebo in accordance with
the legislation and keep the randomisation code until ﬁnali-
zation of the clinical trial. The ﬁnal cell products will be
stored in nitrogen vapour containers until clinical use.
2.3. Cell Treatment. There will be no humane leucocyte anti-
gen (HLA) tissue type matching between the donor and the
patients. The IMP will be thawed and prepared for injection
immediately before treatment. The treatment ampoules are
transparent, and the colour of the placebo product is slightly
diﬀerent from that of the cell product. Therefore, to assure
the blinding of the treatment, the clinical teams which are
responsible for the screening and follow-up of the patients
will not participate in the treatment procedure or be in the
catheterization laboratory during the treatment. The staﬀ in
the catheterization laboratory will be instructed to avoid
comments on the delivered product.
2.4. NOGA-Guided Injection. A 3D map of the left ventricle
will be created using the NOGA XP® system (Biological
Delivery System, Cordis, Johnson & Johnson, USA) [7–10].
With the MYOSTAR® injection catheter (Biological Delivery
System, Cordis, Johnson & Johnson, USA), the IMP (100
million CSCC_ASCs or placebo) will be delivered into the
myocardium by 12–20 injections of 0.3–0.4mL. The injec-
tions will be performed in the viable myocardial tissue
with a unipolar voltage> 6mV. Plasma CKMB and Troponin
will be measured before, immediately after, 6 hours and at
day 1 after the injections in order to assess possible
myocardial eﬀects.
2.5. ECHO and CT Scans. Patients will undergo cardiac
computed tomography (CT) and echocardiography (ECHO)
scans with contrast at baseline and six months after
treatment [8]. For cardiac CT (320 slice, Aquilion, Toshiba,
Tokyo, Japan, or Flash dual source, Siemens, Siemens
Healthcare GmbH, Germany), the R-R interval andmultiseg-
mental image reconstruction will be performed with the most
recent scanner software. ECHO will use parasternal and
apical two 2D and 3D views. CT scans with contrast will
not be performed if plasma creatinine> 130 μmol/L or in
patients with known contrast allergy.
All image data will be stored in a central server and be
analysed blinded. CT scans will be analysed with the cvi42
postprocessing tool (Circle Cardiovascular Imaging, Cal-
gary, Alberta, Canada). Endocardial and epicardial borders
will be traced manually in end-diastole and end-systole
starting from the mitral plane and ending at apex. ECHO
will be analysed using IntelliSpace Cardiovascular
Table 1: Inclusion and exclusion criteria.
Inclusion criteria
(1) 30 to 85 years of age
(2) Signed informed consent
(3) Chronic stable ischemic heart disease
(4) Symptomatic heart failure (NYHA II-III)
(5) Left ventricle ejection fraction (LVEF)≤ 45% documented
by echocardiography at randomisation obtained after up-
titration in heart failure medication (if cardiac resynchroni-
sation therapy device (CRT) 3 months after implantation)
(6) Plasma NT-pro-BNP> 300 pg/mL (>35 pmol/L) in sinus
rhythm and plasma NT-pro-BNP> 422 pg/mL
(>49 pmol/L) in patients with atrial ﬁbrillation
(7) Maximal tolerable heart failure medication
(8) Heart failure medication unchanged two months prior
to inclusion/signature of informed consent. Changes in
diuretics accepted
(9) No option for percutaneous coronary intervention (PCI)
or coronary artery bypass graft (CABG)
(10) Patients who have had PCI or CABG within six months of
inclusion must have a new angiography less than one month
before inclusion and at least fourmonths after the intervention
to rule out early restenosis
(11) Patients cannot be included until three months after
implantation of a CRT or 1 month after an implantable
cardioverter device (ICD)
Exclusion criteria
(1) Heart failure (NYHA I or IV)
(2) Acute coronary syndrome with elevation of CKMB or
troponins, stroke, or transitory cerebral ischemia within six
weeks of inclusion
(3) Other revascularization treatment within four months of
treatment
(4) If clinically indicated that the patient should have a coronary
angiography before inclusion
(5) Moderate to severe aortic stenosis (valve area< 1.3 cm2) or
valvular disease with option for surgery
(6) Diminished functional capacity for other reasons such as
obstructive pulmonary disease with forced expiratory
volume in 1 second (FEV1)< 1 L/min, moderate to severe
claudication, severe arthrosis or severe pain from the
musculoskeletal system, or morbid obesity
(7) Clinical signiﬁcant anaemia (haemoglobin< 6mmol/L),
leukopenia (leucocytes< 2× 109/L), leucocytosis
(leucocytes> 14× 109/L), or thrombocytopenia
(thrombocytes< 50× 109/L)
(8) Anticoagulation treatment that cannot be paused
during cell injections
(9) Patients with reduced immune response
(10) History with malignant disease within ﬁve years of inclusion
or suspected malignancy, except treated skin cancer other
than melanoma
(11) Pregnancy or lactation
(12) Other experimental treatment within four weeks of
baseline tests
(13) Participation in another intervention trial
(14) Known hypersensitivity to dimethyl sulfoxide (DMSO)
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(Philips Medical Systems, Best, the Netherlands) to
obtain conventional as well as deformation and 3D
volumetric measures.
2.6. Biomarkers and Alloantibodies. All donors will have an
intermediate resolution typing of human leucocyte antigen-
(HLA-) A, HLA-B, HLA-C, DRB1, DRB345, DQA1, DQB1,
DPA1, and DPB1 loci by real-time PCR with subsequent
melting point analyses using a Linkseq 384-well complete
typing kit (Linkage Biosciences Inc., CA, US). Patient blood
samples are drawn at baseline and follow-up and will be
stored for later centralized analyses of biomarkers and
the presence of alloantibodies with the LABScreen HLA
classes I and II single antigen bead assay on a Luminex
100 (One Lambda Inc., Thermo Fischer, Canoga/Los
Angeles, CA, USA).
Inclusion criteria met
Patient screening/baseline assessment
Patient signs informed consent
MSC group (n = 54) Control group (n = 27)
NOGA mapping and CSCC_ASC
injection NOGA mapping and placebo injection
Follow-up visits
Randomisation
Figure 1: Design of the MSC-HF II trial. CSCC_ASC: cardiology stem cell centre adipose-derived stromal cells.
Table 2: MSC-HF II study: summary of events.
Event Screening/baseline D1 D2 D3 M1 M3 M6 M12
Informed consent X
History/physical X X X X X X X
NYHA X X X X X X
CCS X X X X X X
ECG X X X X X X X
Biochemistry local laboratory X X X X X X X X
Biomarkers X X X X X X
HLA tissue typing X
HLA tissue antibodies X X X X X
6-minute walking test X X X X
Chest X-ray X
CCT X X X
KCCQ X X X X
SAQ X X X X
EQ5D3L X X X X
NOGA mapping X
IMP injection X
Echocardiography X X X
Holter monitoring X X X X
AE evaluation X X X X X X
D: day; M: month; AE: adverse events; CCS: Canadian Cardiovascular Society functional classiﬁcation; CCT: cardiac computed tomography imaging;
ECG: electrocardiogram; HLA: humane leucocyte antigen; IMP: investigational medicinal product; KCCQ: Kansas City Cardiomyopathy Questionnaire;
NYHA: New York Heart Association functional classiﬁcation; SAQ: Seattle Angina Questionnaire. EQ5D3L questionnaire.
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2.7. Endpoints. The primary endpoint is the diﬀerence
between the two groups of the change in left ventricle end-
systolic volume (LVESV) from baseline to 6-month follow-
upmeasured with CT scans and with ECHO scans in patients
with reduced kidney function.
The secondary endpoints are safely evaluated by the
development of alloantibodies and laboratory safety mea-
surements, incidence and severity of serious adverse events,
and suspected unrelated serious adverse events 1, 3, 6, and
12 months after treatment. Other endpoints are changes in
LVEF, left ventricle end-diastolic volume (LVEDV), stroke
volume, cardiac output, and end-diastolic myocardial mass
at 6-month follow-up. The changes in left ventricle function
will be measured by CT and ECHO.
Other secondary endpoints are changes in NYHA and
CCS class, Kansas City Cardiomyopathy Questionnaire
(KCCQ), Seattle Angina Questionnaire, EQ5D3L Question-
naire, 6-minute walking test, and NT-pro-BNP.
We will also asses changes in the following endpoints
alone and combined:
(1) Death, hospitalization for worsening heart failure
including implanting of a biventricular pacemaker, and hos-
pitalization because of ventricular tachycardia or ﬁbrillation
1, 2, and 3 years after treatment.
(2) Death, hospitalization for any cardiovascular rea-
son, hospitalization for worsening heart failure including
inserting of a biventricular pacemaker, and hospitalization
because of ventricular tachycardia or ﬁbrillation 1, 2, and
3 years after treatment.
2.8. Power Calculation
2.8.1. Deﬁnition and Justiﬁcation (Power Calculation) of
Sample Size. The enrolment of 81 patients in a 2 : 1 randomi-
sation (54 : 27) will have a statistical power above 90% for the
detection of an absolute change between groups in LVESV of
10mL expected SD of 13mL and 11.6mL with expected SD
of 15mL. For all, alpha values of 5% were used. Change
between groups in LVEF of 3.1% with expected SD of 4%
and 3.9% with expected SD of 5% will also have statistical
power above 90% with a 5% alpha value.
Power calculations are based on our recently ﬁnalized
double-blind, placebo-controlled trial with 60 patients with
IHF (MSC-HF trial); we compared direct intramyocardial
injections of autologous MSCs or placebo in a 2 : 1 rando-
misation design. The six-month follow-up demonstrated
signiﬁcant improvement in LVESV with a diﬀerence
between groups of 13.0± 12.9mL (p = 0 001). There were
also signiﬁcant improvements in LVEF with a diﬀerence
of 6.2± 3.8% (p < 0 0001) between MSC and placebo-
treated patients.
In theMSC-HF trial, cardiac measurements were done by
magnetic resonance imaging (MRI) and CT. Since the SD is
often a little higher for echocardiographic measured parame-
ters compared to the data obtained using MRI and CT, we
used slightly higher SD in our power calculations.
2.8.2. Safety and Ethical Considerations. The Cardiology
Stem Cell Centre has conducted several clinical studies with
direct injection of stem cells or genes into the myocardium
with the methodology employed without any safety issues
raised [7–10].
The newly developed CSCC_ASC product has been eval-
uated in 10 patients with IHF without any safety concerns
[12]. Each patient was treated with cells from one of three
donors, and no matching between the donor and the patient
tissue types was performed. There were no procedure-related
complications to the direct intramyocardial injection of
CSCC_ASC. During the 6-month follow-up period, four
out of ten patients developed donor-speciﬁc de novo HLA
class I antibodies and two other patients had prior to the
treatment donor-speciﬁc antibodies. None of the patients
had any clinical symptoms, changes in biochemical parame-
ters, or inﬂammatory signs indicating an immunization.
Based on these data and the safety data from other groups
using allogeneic MSC therapy in patients, we consider it safe
to continue with the present clinical phase II trial.
During the two CT scans, patients may receive a radia-
tion dose of up to 20mSv depending on body weight, heart
rate, and regularity of the heart rate during the scan. It can
be calculated that the lifetime risk of dying from cancer
hereby theoretically increases by 0.1%. The patients receiving
a maximum radiation dose of 20mSv will have their lifetime
risk of dying from cancer increased from 25% to 25.1%. The
above estimation is based on calculations done by the
National Institute of Radiation Protection, Denmark.
3. Discussion
The present described study is the ﬁrst double-blinded, ran-
domised, multicentre, placebo-controlled trial to test the eﬃ-
cacy and safety of a newly developed intramyocardial
delivered allogeneic adipose-derived mesenchymal stromal
cell product CSCC_ASC from healthy donors in patients
with known chronic IHF. The primary eﬃcacy endpoint is
the diﬀerence between the two groups of the change in left
ventricle end-systolic volume (LVESV) from baseline to 6-
month follow up. The LVESV has been chosen based on
the previous demonstration that treatment with beta-
blockers can improve LVESV and that it is a strong prognos-
tic parameter of death in patients with heart failure [15, 16].
The use of autologous MSCs for clinical therapy has
been proven to be safe and with some eﬃcacy as a
regenerative treatment for ischemic heart patients in sev-
eral clinical studies (Tables 3 and 4). However, based on
collected experience from clinical trials, the lack of a
homogenous cell product and dose, as well as timing
and logistics around transportation of autologous cell
therapy, prevents feasibility, repeatability, and dissemina-
tion of regenerative therapy. Therefore, a switch from
autologous to allogeneic ASC therapy is necessary to
propagate cell therapy clinically.
It is well known that there are some diﬀerences between
BM-MSCs and ASCs, in their gene expression proﬁle, their
angiogenic potential, and secretion of factors [29]. It has been
demonstrated that the most discriminative feature for het-
erogeneity within MSC cultures is the tissue source followed
by the culture methodology [30, 31]. In spite of these
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diﬀerences, both cell sources seem to be equally eﬀective clin-
ically (Tables 3 and 4). Since ASCs can be obtained in sub-
stantially greater amounts, they may appear to be a better
choice than BM-MSCs for clinical application [5, 6].
However, there are also many similarities between MSCs
from various tissue sources in morphology, kinetics, sur-
face markers, multipotency, and most intriguingly immune
modulatory capacities [5, 32–35]. Cells are believed to be
able to evade being recognized by the recipient immune
system via modulating the recipient immune function.
This feature makes MSCs worthy candidates for allogeneic
therapy [33–35]. MSCs engage in direct cell-cell interaction
with antigen-presenting cells and secrete a number of factors
to modulate the local environment in a trophic manner. Allo-
geneic MSCs and ASCs have already been used in clinical
trials without any side eﬀects (Tables 3 and 4). Un-blinded
comparative studies between autologous and allogeneic
BM-MSCs in patients with heart failure have demonstrated
safety and clinically meaningful eﬃcacy of allogeneic BM-
MSC versus autologous BM-MSC [22, 24].
Moreover, culture expansion of MSCs is presently
performed in open ﬂasks of varying sizes. The manual proce-
dures needed for changing media are time consuming and
therefore labour extensive, and all pose a great risk for
contamination. Consequently, implementing newly available
closed bioreactor systems with continuous delivery of
medium will minimise contamination risk and improve the
standardisation of the ﬁnal clinical cell product.
At Cardiology StemCell Centre, Rigshospitalet University
Hospital Copenhagen, we have established new cultivation
protocols with human platelet lysate in closed bioreactor
systems for the production of allogeneic CSCC_ASC from
Table 4: Mesenchymal stem cell trials in patients with chronic ischemic heart disease.
Reference
Number of
patients
Cell
type
Design
Delivery
route
Endpoints
Allogeneic
Hare et al. 2012 [22] 30 MSC RO IM Safety and feasible
Perin et al. 2015 [23] 60 MSC RSCT IM Safety and feasible
Kastrup et al. 2017 [12] 10 ASC Open IM Safety and feasible
Hare et al. 2017 [24] 37 MSC Open IM Safety and eﬃcacy
Autologous
Chen et al. 2006 [25] 22 MSC Open IC
Improved LVEF, exercise capacity, and
symptoms
Mohyeddin-Bonab et al. 2007 [26] 8 MSC Open IC Improved LVEF, infarct size, and symptoms
Katritsis et al. 2007 [19] 5 MSC Open IC Not arrhythmogenic
Williams et al. 2011 [27] 4 MSC Open IM Reduced LV dimensions and infarct size
Friis et al. 2011 [7] 31 MSC Open IM
Improved LVEF, exercise capacity, and
symptoms
Lasala et al. 2011 [28] 10 MSC Open IC Increased LVEF
Mathiasen et al. 2014 [10] 60 MSC PPCT IM
Safe, improved LVEF, and increased myocardial
mass
Qayyum et al. 2017 [11] 60 ASC PPCT IM
Safe. Tendency toward improved exercise
capacity
IC: intracoronary; IM: intramyocardial; LV: left ventricular; LVEF: left ventricular ejection fraction; RO: randomised open study; RPCT: randomised placebo
controlled trial; RSCT: randomised sham controlled trial.
Table 3: Mesenchymal stromal cell trials in patients with acute myocardial infarction.
Reference Number of patients Cell type Design Delivery route Endpoints
Allogeneic
Hare et al. 2009 [17] 53 MSC RPCT IV Safe. Improved FEV1
Autologous
Chen et al. 2004 [18] 69 MSC RPCT IC Improved LVEF, LVESV, perfusion
Katritsis et al. 2007 [19] 22 MSC Open IC Improved wall motion and perfusion
Yang et al. 2010 [20] 16 MSC Open IC Safe and feasible. No clinical improvement
Houtgraaf et al. 2012 [21] 14 MSC RPCT IC Improved perfusion and reduced scar tissue
FEV1: forced expiratory volume in 1 second; IC: intracoronary; IV: intravenous; LV: left ventricular; LVEF: left ventricular ejection fraction; RPCT: randomised
placebo controlled trial.
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healthy donors, which can be cryopreserved and stored in
nitrogen vapour containers as an oﬀ-the-shelf product ready
to be used.
This newly developed product has a ﬁrst in man safety
study in patients with IHF-demonstrated safety, feasibility,
and a tendency towards eﬃcacy [12]. Based on these data
and the knowledge from other clinical studies using alloge-
neic mesenchymal cell products for treatment, we have found
it relevant to test the safety and eﬃcacy of CSCC_ASC in a
larger placebo-controlled trial in patients with IHF. If the
same safety and eﬃcacy proﬁle of the present allogeneic
mesenchymal cell product stored as an oﬀ-the-shelf product
as seen with autologous MSCs can be demonstrated, then it
will be an important step towards the implementation of cell
therapy in severely sick IHF patients.
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